Last edition
News about "Chugai Exercises"
Chugai Exercises Option for AraLinQ Technology in USD 780 Million ADC Collaboration
Chugai Pharmaceutical Co., Ltd. has exercised its option to license Araris Biotech AG’s proprietary AraLinQ linker-payload platform, deepening an existing research collaboration aimed at developing next-generation antibody-drug conjugates (ADCs).
Chugai Exercises | 11/02/2026 | By Darshana
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members